Chenodeoxycholic acid - Mirum Pharmaceuticals
Alternative Names: Chenodal®; Chenodiol - Mirum PharmaceuticalsLatest Information Update: 26 Jul 2024
At a glance
- Originator Mirum Pharmaceuticals
- Class Choleretics; Cholic acids; Gallstone therapies; Gastrokinetics; Irritable bowel syndrome therapies
- Mechanism of Action Cholesterol modulators; Cholesterol synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Cerebrotendinous xanthomatosis
Most Recent Events
- 13 Jul 2024 Chenodeoxycholic acid - Mirum Pharmaceuticals receives Orphan Drug status for Cerebrotendinous xanthomatosis in USA, as at March 2010
- 28 Jun 2024 Preregistration for Cerebrotendinous xanthomatosis (In adolescents, In children, In the elderly, In infants, In adults) in USA (PO)
- 04 Oct 2023 Mirum Pharmaceuticals completes the phase III RESTORE trial in Cerebrotendinous xanthomatosis (In infants, In children, In adolescents, In adults, In the elderly) in Brazil, USA (PO) (NCT04270682)